Neoprobe reported first-quarter revenues of $1.5 million, up 45% compared with the $1.1 million booked in the same period last year. For the quarter (end-March 31), the Dublin, OH-based developer of oncology and cardiovascular surgery products had a net loss of $479,000, compared with a net loss of $845,000 last year.
The improvements reflected the continuation of positive trends in the firm's gamma surgery business and the impact of expense-control initiatives implemented in 2002, said president and CEO David Bupp. He said that the firm is on track to meet its goals for the year.
By AuntMinnie.com staff writers
May 8, 2003
Related Reading
Neoprobe begins delivering Qauntix/OR, April 28, 2003
Neoprobe shows loss in 2002, February 20, 2003
Neoprobe launches Quantix, November 21, 2002
Neoprobe’s Q3 revenues sag, November 13, 2002
Neoprobe gets clearance for FlowGuard, February 28, 2002
Copyright © 2003 AuntMinnie.com
